Printer Friendly

IMMUNOGEN, INC. NAMES ROBERT E. TELLIS VICE PRESIDENT OF CORPORATE DEVELOPMENT

 CAMBRIDGE, Mass., Feb. 16 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the appointment of Robert E. Tellis as vice president, corporate development, a newly created position. From 1986 to the present, Tellis was vice president, corporate planning, at CIBA-Corning Diagnostics.
 "We are especially pleased to have Bob Tellis join ImmunoGen at this stage of our development," states Donald J. McCarren, president and chief operating officer. "Clinical trials with our immunoconjugates are demonstrating the applicability and value of our core technology for improved cancer treatment. To fully exploit the value of our technology, we are making key product development decisions and constructing a long-term strategic plan. As part of that plan, ImmunoGen will begin the generation of near-term revenues in collaboration with third parties. Bob will lead the expansion of these activities as we enter into new agreements and partnerships for product development and marketing."
 As vice president, corporate planning, at CIBA-Corning Diagnostics, Tellis was responsible for the creation of that company's mid- and long- range plans, in- and out-licensing of products and assessment of new opportunities, acquisitions and divestitures. He was chairman of the Business Development Committee and a member of the Corporate Management Committee. From 1981 to 1986, Tellis was executive director, licensing, for CIBA-Geigy Pharmaceuticals. He held various other management positions with CIBA-Geigy from 1986 to 1983. Tellis holds a J.D. and an M.B.A. from St. John's University and a B.S. from Fordham University.
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins and drugs conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first- generation products, the Oncolysins(R), are designed for use as post- remission consolidation therapy. The company's small-drug immunoconjugates are intended for use as tumor debulking agents.
 -0- 2/16/93
 /CONTACT: Mark Ratner, director, external communications, of ImmunoGen, Inc., 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PER

SJ -- NE005 -- 6798 02/16/93 10:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 16, 1993
Words:335
Previous Article:SEISMED INSTRUMENTS ANNOUNCES FIRST QUARTER RESULTS
Next Article:MASSMUTUAL REPORTS STRONG FINANCIAL PERFORMANCE FOR 1992
Topics:


Related Articles
IMMUNOGEN EXPANDS MANAGEMENT TEAM: DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER
IMMUNOGEN, INC. NAMES ROBERT J. CONNAUGHTON, JR., GENERAL COUNSEL
IMMUNOGEN, INC., PROMOTES TWO IN RESEARCH AND DEVELOPMENT AND ANNOUNCES THE RESIGNATION OF ITS VICE PRESIDENT, CORPORATE DEVELOPMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters